Clinical Trials Logo

Hereditary Angioedema clinical trials

View clinical trials related to Hereditary Angioedema.

Filter by:

NCT ID: NCT02125162 Completed - Clinical trials for Hereditary Angioedema

A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of the study is to compare how the body takes up and then eliminates the study drug BCX4161 when it is taken orally as a hard gelatin capsule and as a soft gelatin capsule. This study will also evaluate whether food has any effect on how the body takes up BCX4161.

NCT ID: NCT01984788 Completed - Clinical trials for Hereditary Angioedema

Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE

OPuS-1
Start date: November 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic treatment is safe and effective in reducing the number of acute attacks in patients with hereditary angioedema.

NCT ID: NCT01679912 Completed - Clinical trials for Hereditary Angioedema

A Call Center During HAE Attacks (SOS HAE)

SOS AOH
Start date: March 2013
Phase: Phase 4
Study type: Interventional

This clinical trial aims to compare morbidity and cost associated with acute attacks of hereditary angioedema in patients with an intervention based on a support after a phone call to the call center (SOS HAE) from a group of patients does not change their practice.

NCT ID: NCT01457430 Completed - Clinical trials for Hereditary Angioedema

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

IHA
Start date: December 2011
Phase: Phase 4
Study type: Interventional

The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.

NCT ID: NCT01426763 Completed - Clinical trials for Hereditary Angioedema

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Start date: September 12, 2011
Phase: Phase 2
Study type: Interventional

The objectives of the study are to: 1. Evaluate the safety and tolerability of subcutaneously administered CINRYZE with recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE) who previously participated in CINRYZE Study 0624-200 (NCT01095497) 2. Characterize the pharmacokinetics and pharmacodynamics of subcutaneously administered CINRYZE with rHuPH20 3. Assess the immunogenicity of CINRYZE following subcutaneous (SC) administration of CINRYZE with rHuPH20

NCT ID: NCT01359969 Completed - Clinical trials for Hereditary Angioedema

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Start date: January 17, 2012
Phase: Phase 2
Study type: Interventional

This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.

NCT ID: NCT01188564 Completed - Clinical trials for Hereditary Angioedema

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Start date: January 2011
Phase: Phase 3
Study type: Interventional

This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in Hereditary Angioedema (HAE) patients.

NCT ID: NCT01095497 Completed - Clinical trials for Hereditary Angioedema

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

Start date: June 7, 2010
Phase: Phase 2
Study type: Interventional

The objectives of the study are to: 1. Evaluate the safety and tolerability of CINRYZE administered by subcutaneous injection in subjects with hereditary angioedema 2. Characterize the pharmacokinetics and pharmacodynamics of CINRYZE administered by subcutaneous injection 3. Assess the immunogenicity of CINRYZE following subcutaneous administration

NCT ID: NCT01005888 Completed - Clinical trials for Hereditary Angioedema

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Start date: March 14, 2005
Phase: Phase 3
Study type: Interventional

The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.

NCT ID: NCT00997204 Completed - Clinical trials for Hereditary Angioedema

EASSI - Evaluation of the Safety of Self-Administration With Icatibant

EASSI
Start date: September 25, 2009
Phase: Phase 3
Study type: Interventional

This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.